Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSEMKT:AMPE
- CUSIP: 03209T10
- Web: N/A
- Market Cap: $43.55 million
- Outstanding Shares: 57,242,000
- 50 Day Moving Avg: $0.71
- 200 Day Moving Avg: $0.83
- 52 Week Range: $0.52 - $4.19
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.00
- P/E Growth: 0.0000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.09 per share
- Price / Book: 8.65
- Average Volume: 335,311 shs.
- Short Ratio: 23.83
Frequently Asked Questions for Ampio Pharmaceuticals (NYSEMKT:AMPE)
What is Ampio Pharmaceuticals' stock symbol?
Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AMPE."
How were Ampio Pharmaceuticals' earnings last quarter?
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) issued its quarterly earnings data on Tuesday, February, 24th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.01. View Ampio Pharmaceuticals' Earnings History.
Who are some of Ampio Pharmaceuticals' key competitors?
Some companies that are related to Ampio Pharmaceuticals include Pernix Therapeutics Holdings (PTX), Allergan plc (ACT), Auxilium Pharmaceuticals (AUXL), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK), Optimer Pharmaceuticals (OPTR), Questcor Pharmaceuticals (QCOR), Salix Pharmaceuticals (SLXP), Santarus (SNTS), Shire Viropharma (VPHM) and Warner Chilcott Plc (WCRX).
How do I buy Ampio Pharmaceuticals stock?
Shares of Ampio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ampio Pharmaceuticals stock cost?
One share of Ampio Pharmaceuticals stock can currently be purchased for approximately $0.76.
Consensus Ratings for Ampio Pharmaceuticals (NYSEMKT:AMPE) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
(Data available from 5/28/2015 forward)
|6/30/2016||Janney Montgomery Scott||Reiterated Rating||Positive|
Earnings History for Ampio Pharmaceuticals (NYSEMKT:AMPE)Earnings History by Quarter for Ampio Pharmaceuticals (NYSEMKT:AMPE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Current Year EPS Consensus Estimate: $-0.6100 EPS
Next Year EPS Consensus Estimate: $-0.1900 EPS
Dividend History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Ampio Pharmaceuticals (NYSEMKT:AMPE)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Ampio Pharmaceuticals (NYSEMKT:AMPE)
Latest Headlines for Ampio Pharmaceuticals (NYSEMKT:AMPE)